Results 171 to 180 of about 13,569 (208)

Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T Levels [PDF]

New England Journal of Medicine, 1999
BACKGROUND: In patients with refractory unstable angina, the platelet glycoprotein IIb/IIIa-receptor antibody abciximab reduces the incidence of cardiac events before and during coronary angioplasty.
Christian W Hamm
exaly   +4 more sources

Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction

New England Journal of Medicine, 2002
G. Stone, C. Grines, D. Cox, Eulogio J. García, J. Tcheng, John J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, J. Carroll, B. Rutherford, A. Lansky   +11 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Intracoronary tenecteplase versus abciximab as adjunctive treatment during primary percutaneous coronary intervention in patients with anterior myocardial infarction.

EuroIntervention, 2019
AIMS We sought to compare the effects of intracoronary administration of a fibrinolytic drug (tenecteplase) to those of a glycoprotein IIb/IIIa inhibitor (abciximab) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary ...
Francisco J. Morales-Ponce, Francisco J. Lozano-Cid, P. Martínez-Romero, Pablo J. González-Pérez, J. Sánchez-Brotons, I. Diaz-Torres, J. C. Rodríguez-Yáñez, Pilar Caro-Mateo, A. Serrador-Frutos   +8 more
semanticscholar   +1 more source

Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment

Journal of NeuroInterventional Surgery, 2018
Background A stent is often necessary for the treatment of stroke. In such cases,it is essential for the patient to have antiplatelet therapy.
F. Delgado, R. Oteros, E. Jiménez-Gómez, I. Bravo Rey, M. D. Bautista, R. Valverde Moyano   +5 more
semanticscholar   +1 more source

A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel

New England Journal of Medicine, 2004
Adnan Kastrati, Peter B Berger
exaly   +2 more sources

Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction

New England Journal of Medicine, 2011
Adnan Kastrati, Stefanie Schulz, Steffen Massberg   +2 more
exaly   +2 more sources

Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization

New England Journal of Medicine, 2001
Eric J Topol
exaly   +2 more sources

Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial

Lancet, The, 2012
Holger Thiele, Jochen Wöhrle, Ingo Eitel   +2 more
exaly   +2 more sources

Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial

Lancet, The, 2008
Carlo D Di Mario, Konstantinos Dimopoulos, Achille Gaspardone   +2 more
exaly   +2 more sources

Effect of polymer-free TiO2 stent coated with abciximab or alpha lipoic acid in porcine coronary restenosis model.

Journal of Cardiology, 2014
BACKGROUND Polymer-free drug-eluting stents (DES) may overcome the shortcomings of polymer-based DES. The aim of this study was to examine the effect of the polymer-free TiO2 film-coated stent with abciximab or alpha lipoic acid in a porcine coronary ...
K. Lim, M. Jeong, I. Bae, Jun-Kyu Park, D. Park, Jong Min Kim, Jung Ha Kim, Hyung-Seok Kim, Yong Sook Kim, Hye-yun Jeong, Sun-jung Song, Eun Ju Yang, D. Cho, D. Sim, K. Park, Y. Hong, Y. Ahn   +16 more
semanticscholar   +1 more source